An interventional study of Artificial intelligence-assisted chest X-ray in TB screening and Routine doctors analyze the process of chest X-rays in Tuberculosis (TB), sponsored by Xuelin Yang. Recruiting at 1 site in China. Open to participants aged 15 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by Xuelin Yang · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Tuberculosis with a site in China — 22 open to participants now, 25 under way, 5 of them phase 3. Tuberculosis · China.
Among the 62 studies in Tuberculosis with a site in China, this one is the 2nd largest by planned enrollment of the 47 interventional ones that give a count, is one of 8 that started in 2025, is one of 11 with no phase, reaches primary completion later than 19 of the 24 other live ones, and was the 52nd registered.
1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.
Browse Tuberculosis studies →22 of the 62 studies in Tuberculosis with a site in China are open now. Recruiting first, the newest first:
Huashan Hospital · Sites in China
Ages 3 mo–18 yrs
Beijing Chest Hospital, Capital Medical University · Sites in China
Ages 18–100 · Healthy volunteers
Huashan Hospital · Sites in China
Ages 14–80
WestVac Biopharma Co., Ltd. · Sites in China
Ages 14+
Chengdu CoenBiotech Co., Ltd · Sites in China
Ages 3+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.
This study: 15 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 13 · Phase 3 10 · Phase 4 6
First in 2004; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 22,000 is above the median of 150 across 822 interventional studies indexed under Tuberculosis.
Median enrollment 241 across the 47 interventional studies, 500 across the 15 observational. Of the 26 that completed or were terminated, 3 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 62 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Xuelin Yang as lead sponsor.
Xuelin Yang has 1 study filed under Tuberculosis — fewer than ten, so there is no comparison to draw.
4 of the studies in Tuberculosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07575061Beijing Chest Hospital, Capital Medical UniversityA 15-year Cohort Study on Risk Factors of Mortality in Patients With Intestinal Tuberculosis | 2026-12-01 |
| NCT07459569China-Japan Friendship HospitalDiagnostic Performance and Safety of Endobronchial Ultrasound-guided Transbronchial Mediastinal Cryobiopsy in Diagnosing Tuberculous Mediastinal Lymphadenitis: a Randomised Controlled Trial | 2027-05 |
| NCT06153069Huashan HospitalAsymptomatic TB With Innovative Modified Short-course Regimens | 2027-11 |
| NCT07893444Huashan HospitalBRIGHT-Child TB: Short-Course Treatment for Non-Severe Pulmonary Tuberculosis in Children | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 62 studies in Tuberculosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The global incidence rate and mortality of tuberculosis (TB) pose a challenge to achieving the goals set out in the tuberculosis eradication strategy and the SDGs by 2030. At present, timely and accessible early detection methods for tuberculosis are still a major obstacle. In this context, the emergence of artificial intelligence (AI), especially the AI-assisted chest X-ray (CXR) in the field of diagnostic imaging, has proved the potential to significantly improve the speed and accuracy of tuberculosis diagnosis. However, the extent to which these technologies can affect the broader tuberculosis care cascade, especially by reducing the diagnostic time in the population level, has not yet been explored. The proposed project plans to use the certified AI-assisted CXR system (JF CXR-1) for tuberculosis screening, which aims not only to integrate AI into the diagnosis process, but also to critically assess its impact on the overall tuberculosis care cascade. The selected location for this project is Yichang City in western Hubei Province, China, which is facing a high TB burden. The city has established a strong city-wide health big data platform ten years ago, providing the basis for this project. The project will first optimize the AI-assisted CXR system through retrospective imaging to validate the accuracy of case screening (Stage Ⅰ). Secondly, the project will shift its focus to the real world, where cluster randomized controlled trials will be conducted in primary-care settings (Stage Ⅱ). In this stage, the effectiveness of the AI-assisted CXR system in reducing the diagnostic time of TB cases will be evaluated by comparing with those settings without using the tool. In stage Ⅲ, the qualitative and quantitative methods will be used to evaluate the generalization, practicality, and feasibility of extending the screening strategy in various community environments. If the AI-assisted screening strategy is proven accurate, effective, and sustainable, it may pave the way for its widespread adoption in primary healthcare institutions and other grassroots areas in China. This can not only improve the timeliness of tuberculosis diagnosis, but also help to allocate medical resources more effectively and significantly reduce tuberculosis-related incidence and mortality, bringing positive changes to global public health. In addition, the results of the project can also provide information for policy decisions and guide the formulation of strategies to prioritize the integration of AI into health care, which can not only fight against tuberculosis but also a series of other diseases.
Research Plan
After the completion of the chest DR Examination, the chest X-ray was analyzed by the artificial intelligence-assisted system (JF CXR-1) to identify the potential signs of tuberculosis. Meanwhile, the doctor analyzed the results of the chest X-ray. After the analysis results were confirmed, the initial judgment results of the doctor and the analysis results of the artificial intelligence-assisted system were recorded, and the reading results of the artificial intelligence-assisted system were fed back to the doctor. Review the doctor's comprehensive analysis results of the artificial intelligence-assisted system, make a final judgment on the chest X-ray results, and determine whether further relevant examinations (such as etiological examination, CT examination, etc.) are needed. Record the doctor's judgment results.
Follow up and record the time of diagnosis reported by the tuberculosis specific disease system.
3.2 Control Group The subjects who visited the township medical and health institutions in the control group, underwent chest DR Examinations, and signed the informed consent form were included in the control group, and the visiting time was recorded.
After the chest DR Examination is completed, a regular doctor reviews the films without using an artificial intelligence-assisted system. Once the results of the regular doctor's review are confirmed, a final judgment is made on whether further related examinations (such as etiological tests, CT scans, etc.) are needed, and the doctor's judgment is recorded.
Follow up and record the time of diagnosis reported by the tuberculosis specific disease system.
Eligibility criteria Inclusion criteria
Participants must receive medical treatment at the primary healthcare hospitals in Yichang City, Hubei Province, and underwent chest X-ray examinations. The participants have to meet the following criteria:
Exclusion criteria
Those who meet any of the below criteria will be excluded:
Withdrawal Criteria
Diagnostic Test: Artificial intelligence-assisted chest X-ray in TB screening
Other: Routine doctors analyze the process of chest X-rays
After the completion of the chest DR Examination, the chest X-ray was analyzed by the artificial intelligence-assisted system (JF CXR-1) to identify the potential signs of tuberculosis. Meanwhile, the doctor analyzed the results of the chest X-ray. After the analysis results were confirmed, the initial judgment results of the doctor and the analysis results of the artificial intelligence-assisted system were recorded, and the reading results of the artificial intelligence-assisted system were fed back to the doctor. Review the doctor's comprehensive analysis results of the artificial intelligence-assisted system, make a final judgment on the chest X-ray results, and determine whether further relevant examinations (such as etiological examination, CT examination, etc.) are needed. Record the doctor's judgment results. Follow up and record the time of diagnosis reported by the tuberculosis specific disease system.
After the chest DR Examination is completed, a regular doctor reviews the films without using an artificial intelligence-assisted system. Once the results of the regular doctor's review are confirmed, a final judgment is made on whether further related examinations (such as etiological tests, CT scans, etc.) are needed, and the doctor's judgment is recorded. Follow up and record the time of diagnosis reported by the tuberculosis specific disease system
The difference in the diagnostic yield of pulmonary tuberculosis screening in township medical and health institutions between the intervention group and the control group.
Diagnostic yield = The number of people who visited the hospital for chest DR Examination and were ultimately determined to require further relevant examinations and were diagnosed in the tuberculosis specific disease reporting system/the number of people who underwent chest DR Examination
Time frame: pre-intervention (via retrospective analysis of historical data), post-intervention (six and twelve months after the intervention starts)
The difference in the average number of days from visiting township medical and health institutions to the diagnosis of pulmonary tuberculosis between patients in the intervention group and the control group
The number of days for confirmed diagnosis = the time of diagnosis reported by the tuberculosis specific disease system - the time of the patient's visit
Time frame: pre-intervention (via retrospective analysis of historical data), post-intervention (six and twelve months after the intervention starts)
The differences in the accuracy of different tuberculosis screening strategies between the intervention group and the control group
The differences in the accuracy of different tuberculosis screening strategies between the intervention group and the control group, including sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, Youden index, and AUC
Time frame: pre-intervention (via retrospective analysis of historical data), post-intervention (six and twelve months after the intervention starts)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Gender, age, tuberculosis diagnosis situation, diagnosis delay situation, detection rate situation, AI accuracy
Supporting information: Study protocol, Statistical analysis plan
Time frame: January 2025 - December 2027
Access criteria: Personnel who have been approved by the research leader can access the declassified data
Started Sep 2025 (actual). Primary completion is estimated for Dec 2027, 27 months after the start.
Of 169 non-industry interventional studies with no phase under Tuberculosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's planned 27 months is close to that.
Counting every sponsor, half of 171 studies reached it within 25 months; a quarter within 14 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.